Discover Ono Pharmaceutical's groundbreaking patent for autophagy-inhibiting compounds, targeting various cancers with innovative MEK inhibitors like selumetinib.

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

While neoadjuvant therapy in stage III or great melanoma is already the standard of care, new research presented at ESMO ...

CaMKII activates the HRI/eIF2α signaling pathway and inhibits the proteotoxicity induced by proteasome inhibition through ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Innovative use of lipid nanoparticles to deliver immune agonists shows promise in activating anti-tumor immunity in ...

Replimune's cash runway supports its accelerated approval and phase 3 trial. See why I think REPL's current low stock price ...

Citation: PARP1 selective inhibitor yields potent and durable antitumor activity in patient-derived preclinical models (2024, September 3) retrieved 23 September 2024 from https://medicalxpress ...

Ruscetti's previous research demonstrated that two cancer drugs (MEK inhibitor trametinib and CDK4/6 inhibitor palbociclib, or T/P) can promote blood vessel development, enabling greater T cell ...

The approval of the BRAF–MEK duo was based on results of the phase II PHAROS trial, which assessed its efficacy and safety in both newly diagnosed and previously treated patients with metastatic NSCLC ...

Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer, with a low five-year survival rate of 13%. It is the third largest cause of cancer death. The microenvironment around ...